The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance
about
sameAs
Anaphylactic reactions to oligosaccharides in red meat: a syndrome in evolution.Cancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reactionKidney xenotransplantationAllogeneic tumor cell vaccines: the promise and limitations in clinical trialsThe alpha-gal story: lessons learned from connecting the dots.Role of α-gal epitope/anti-Gal antibody reaction in immunotherapy and its clinical application in pancreatic cancerStructures of Complexes of a Metal-independent Glycosyltransferase GT6 from Bacteroides ovatus with UDP-N-Acetylgalactosamine (UDP-GalNAc) and Its Hydrolysis ProductsCoping with cross-reactive carbohydrate determinants in allergy diagnosisCharacteristics of α-Gal epitope, anti-Gal antibody, α1,3 galactosyltransferase and its clinical exploitation (Review)Gut microbiota elicits a protective immune response against malaria transmissionAnaphylaxis to the carbohydrate side chain alpha-galCarbohydrates as allergens.Delayed clinical and ex vivo response to mammalian meat in patients with IgE to galactose-alpha-1,3-galactoseDelayed anaphylaxis to red meat masquerading as idiopathic anaphylaxis.Drug allergens and food--the cetuximab and galactose-α-1,3-galactose story.Galactose-α-1,3-galactose and delayed anaphylaxis, angioedema, and urticaria in children.IgE production to α-gal is accompanied by elevated levels of specific IgG1 antibodies and low amounts of IgE to blood group B.Determinants of food allergy.CD1d protein structure determines species-selective antigenicity of isoglobotrihexosylceramide (iGb3) to invariant NKT cellsDelayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-alpha-1,3-galactoseThe carbohydrate galactose-alpha-1,3-galactose is a major IgE-binding epitope on cat IgA.Role of sialic acid for platelet life span: exposure of beta-galactose results in the rapid clearance of platelets from the circulation by asialoglycoprotein receptor-expressing liver macrophages and hepatocytes.The alphaGal epitope of the histo-blood group antigen family is a ligand for bovine norovirus Newbury2 expected to prevent cross-species transmission.Metabolic engineering of Agrobacterium sp. strain ATCC 31749 for production of an alpha-Gal epitope.Parasite Carbohydrate Vaccines.Endotoxemia is associated with altered innate and adaptive immune responses in untreated HIV-1 infected individuals.Glycosylation of mouse and human immune cells: insights emerging from N-glycomics analyses.Immunogenicity of intensively decellularized equine carotid arteries is conferred by the extracellular matrix protein collagen type VI.L-Rhamnose-containing supramolecular nanofibrils as potential immunosuppressive materials.Bovine norovirus: carbohydrate ligand, environmental contamination, and potential cross-species transmission via oysters.An improved Fc function assay utilizing CMV antigen-coated red blood cells generated with synthetic function-spacer-lipid constructs.Identification of galactose-α-1,3-galactose in the gastrointestinal tract of the tick Ixodes ricinus; possible relationship with red meat allergy.Confocal laser scanning microscopy evaluation of an acellular dermis tissue transplant (Epiflex®)Function characterization of a glyco-engineered anti-EGFR monoclonal antibody cetuximab in vitro.Retargeting pre-existing human antibodies to a bacterial pathogen with an alpha-Gal conjugated aptamerThe αGal HyperAcute(®) Technology: enhancing immunogenicity of antiviral vaccines by exploiting the natural αGal-mediated zoonotic blockade.Polysaccharide responsiveness is not biased by prior pneumococcal-conjugate vaccinationThe genomic sequence of the Chinese hamster ovary (CHO)-K1 cell lineExposure to common food additive carrageenan alone leads to fasting hyperglycemia and in combination with high fat diet exacerbates glucose intolerance and hyperlipidemia without effect on weight.Carrageenan Inhibits Insulin Signaling through GRB10-mediated Decrease in Tyr(P)-IRS1 and through Inflammation-induced Increase in Ser(P)307-IRS1
P2860
Q21245667-5ABD6878-EC3D-4E8D-A4A0-F773287C26A0Q26777542-F819F587-0583-47FB-8709-F5A6B632871BQ26822638-D52FC29E-E11C-4B25-A083-71B758F45E14Q26852333-2AB6CFB0-279F-427D-8F13-0B55CC1DC9D1Q27023451-99905C78-FF6E-49ED-87BF-DB78EB7CA143Q27024368-2FB8593F-2270-415A-8022-BCED3E8B8220Q27681445-980FF541-FF4B-460E-AF12-80F5B7AE47DFQ28078253-A3CD45CB-0E01-49F5-A85A-93676E968E5DQ28084522-2C24F400-761E-4D81-AA8C-C92E9531B437Q28253398-CB00A5C8-94B1-49C9-B89B-1B575DB140E5Q30300243-2C564DAB-9AF7-4A11-8AC8-DA2DB655EDDEQ30301262-FBDABFDF-0FA5-45F0-B081-97C7FE3376AEQ30384427-16F749D8-93C4-40A8-8179-039B39235AEFQ30405517-C3561559-B75E-4A80-8772-DB87665AFB71Q30408267-F476E07C-76CF-4435-8CAB-29352FA81C89Q30413582-5F08B3F5-A54F-4AC4-83C4-CC44D3A144CAQ30422478-8C0B5CF7-BFFD-4725-B81A-E8C4F746FE77Q30422603-AFF1524A-0271-4AC6-ACF9-3C3028BE3D0BQ30425388-E88AEECF-426A-4ED1-A51F-B7CBC9EEE375Q30427410-A4A740CC-2892-4E5C-BBE9-053F215AEF4FQ30427723-A0C168D1-3385-478E-A38E-E2EC64DF14DFQ33384971-70789F0D-2FD9-4B99-A775-EB6E34471A8AQ33478403-E103951C-B800-4515-BD31-48086086600BQ33638602-4CCE761A-C97D-476F-82CD-BD319E46BE3CQ33785863-A6465BCB-14D4-4D1F-902B-C00FF02E6162Q33952268-21B3DCE2-0E0A-4B24-A7F2-4D93051D0618Q34026756-8C53185D-8CDE-4AAC-9E48-556EFB36B6B7Q34090198-B4ED6157-6598-4F58-A017-70561EBEC578Q34162945-A448E85E-5311-49A6-9AEA-78EBB8D0A275Q34177706-2B06AC99-E164-4917-8029-CC4B34485DB3Q34199781-079DFE75-B50F-4A4D-9959-C631478D601CQ34328060-9328A0E8-A28C-4500-A309-2B462293E60BQ34441045-AA5E904C-615B-4A18-801D-CCDD1FAB628AQ34451930-9444B6A1-0BAE-4DA8-83E5-15DFEBE127A8Q34474963-6A890818-1596-472D-B9B2-3391E9272719Q34984225-82D765CF-2ACA-417A-8BE9-F654007FDF14Q35022547-9F3CA497-9A7E-4A5F-B293-E4A930AFD140Q35188192-AB68727C-A3DB-493F-A75D-C83401B77C23Q35324612-01AC309B-6AC2-4CA4-A444-EB7724E04153Q35536252-9A73203E-6C40-481C-9314-89DD243F9B23
P2860
The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance
description
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2008
@ast
scientific article (publication date: February 2008)
@en
vedecký článok (publikovaný 2008-02)
@sk
wetenschappelijk artikel (gepubliceerd in 2008-02)
@nl
wissenschaftlicher Artikel
@de
наукова стаття, опублікована в лютому 2008
@uk
مقالة علمية (نشرت في فبراير 2008)
@ar
name
The Galalpha1,3Galbeta1,4GlcNA ...... olution and clinical relevance
@ast
The Galalpha1,3Galbeta1,4GlcNA ...... olution and clinical relevance
@en
The Galalpha1,3Galbeta1,4GlcNA ...... olution and clinical relevance
@nl
type
label
The Galalpha1,3Galbeta1,4GlcNA ...... olution and clinical relevance
@ast
The Galalpha1,3Galbeta1,4GlcNA ...... olution and clinical relevance
@en
The Galalpha1,3Galbeta1,4GlcNA ...... olution and clinical relevance
@nl
prefLabel
The Galalpha1,3Galbeta1,4GlcNA ...... olution and clinical relevance
@ast
The Galalpha1,3Galbeta1,4GlcNA ...... olution and clinical relevance
@en
The Galalpha1,3Galbeta1,4GlcNA ...... olution and clinical relevance
@nl
P2860
P3181
P1476
The Galalpha1,3Galbeta1,4GlcNA ...... olution and clinical relevance
@en
P2093
Bruce A Macher
Uri Galili
P2860
P3181
P356
10.1016/J.BBAGEN.2007.11.003
P407
P577
2008-02-01T00:00:00Z